«Drugmakers have been looking for new ways to differentiate their products from rival therapies amid difficulties in growing insulin sales. Indianapolis-based Lilly hit upon medical devices and an associated connected ecosystem as a way to prevent its diabetes business from becoming obsolete.»

«Tempo is the culmination of the strategy Lilly outlined years ago. The platform has three components: Tempo Smart Button, a Food and Drug Administration-cleared device that records information about the delivery of insulin and shares it via Bluetooth; TempoSmart, an app that records insulin dose information and enables patients to share it with healthcare providers; and Tempo Pen, an insulin delivery device.»

Article written by Nick Paul Taylor



Med Tech Dive